A docking study of a set of several 1,5-disubstituted tetrazoles compounds has been performed to predict the poses of some potential inhibitors of the Abelson tyrosine-protein kinase and the mutated Abelson tyrosine-protein kinase T315I. The study was conducted through Lamarckian genetic algorithms in Autodock4 package. Bayesian calculations were performed; specificity and sensitivity values as well as positive predicted values, and negative predicted values were calculated using a set of 99 known experimentally active ligands and 385 decoys for the Abelson tyrosine-protein kinase from the Directory of Useful Decoys database. Root mean square deviation values were calculated though the X-ray crystallographic data of the bioactive pose of imatinib as reference, and the pose obtained with the above methods. The obtained results show the importance of the protein interactions with the halogens present in some of these 1,5-disubstituted tetrazoles ligands, as well as the presence of some hydrophobic fragments, obtained via the pharmacophoric model, concluding that the eight novels 1,5-disubstituted tetrazoles compounds herein identified, could be effective inhibitors of Abelson tyrosine-protein kinase, using a docking calculations.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Abelson HT, Rabstein LS (1970) Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 30:2213–2222 (Published August 1970)
Auffinger P, Hays FA, Westhof E, Shing Ho P (2004) Halogen bonds in biological molecules. Proc Natl Acad Sci USA 101:16789–16794. https://doi.org/10.1073/pnas.0407607101
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sabele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European Leukemia Recommendations for the management of chronic myeloid leukemia. Blood 122:872–884. https://doi.org/10.1182/blood-2013-05-501569
Ben-Neriah YQ, Daley G, Mes-Masson AN, Witte O, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–214. https://doi.org/10.1126/science.3460176
Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:403–502. https://doi.org/10.1038/nrd839
Casewit CJ, Colwell KS, Rappé AK (1992) Application of a universal force field to organic molecules. J Am Chem Soc 114:10035–10046. https://doi.org/10.1021/ja00051a041
Cavallo G, Metrangolo P, Milani R, Pilati T, Priimagi A, Resnati G, Terraneo G (2016) The halogen bond. Chem Rev 116:2478–2601. https://doi.org/acs.chemrev.5b00484
Colicelli J (2011) ABL tyrosine kinases: evolution of function, regulation, and specificity. Science Signal 3:139 re6. https://doi.org/10.1126/scisignal.3139re6
Cortes-García CJ, Jácome A, Rentería A, Gámez R (2016) Synthesis of 1,5-disubstituted tetrazoles containing a fragment of the anticancer drug imatinib via a microwave-assisted Ugi-azide reaction. Monat Chem 147:1277–1290. https://doi.org/10.1007/s0070
Cousins KR (2011) Computer review of ChemDraw ultra 12.0. J Am Chem Soc 133:8388. https://doi.org/10.1021/ja204075s
Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW (2007) Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Biol Cryst 63:80–93. https://doi.org/10.1107/S0907444906047287
Desogus A, Schenone S, Brullo C, Tintori C, Musumeci F (2015) Bcr-Abl tyrosine kinase inhibitors: a patent review. Exp Opin Ther Pat 25:1–16. https://doi.org/10.1517/13543776.2015.11012155
Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11:905–919. https://doi.org/10.1038/nprot.2016.051
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng GJL, Hada M, Ehara MKR, Fukuda J, Hasegawa M, Ishida T, Nakajima Y, Honda O, Kitao H, Nakai T Vreven JA, Montgomery Jr. JE, Peralta F, Ogliaro M, Bearpark JJ, Heyd E, Brothers KN, Kudin VN, Staroverov R, Kobayashi J, Normand K, Raghavachari A, Rendell JC, Burant SS, Iyengar J, Tomasi M, Cossi N, Rega JM, Millam M, Klene JE, Knox JB, Cross V, Bakken C, Adamo J, Jaramillo R, Gomperts RE, Stratmann O, Yazyev AJ, Austin R, Cammi C, Pomelli JW, Ochterski RL, Martin K, Morokuma VG, Zakrzewski GA, Voth P Salvador JJ, Dannenberg S, Dapprich AD, Daniels Ö, Farkas JB, Foresman JV, Ortiz J, Cioslowski, Fox DJ (2009) Gaussian 09, revision E.01. Gaussian, Inc., Wallingford
Gallardo S, Ocampo AL, Contreras CA, Chacón L (2014) Synthesis and docking studies of the novel N-(2,2-di(1H-pyrrol-2-yl)ethyl)adamantane-1-carboxamide, a potential 11β-HSD1 inhibitor. J Chem Hindawi. https://doi.org/10.1155/2014/294246
Ghaaliq A, McCluskey A (2008) Clinical tests: sensitivity and specificity. Continuing education in anaesthesia. Criti Care Pain 8:221–223. https://doi.org/10.1093/bjaceaccp/mkn041
Hantschel O, Superti-Furga G (2004) Regulation of the C-ABL and BCR-ABL tyrosine kinases. Nat Rev Mol Cell Biol 5:33–44. https://doi.org/10.1038/nrm1280
Huang N, Schoichet BK, Irwing JJ (2006) Benchmarking sets for molecular docking. J Med Chem 49:6789–6801. https://doi.org/10.1021/jm0608356
Iwari A, Panigrahi SK (2007) HBAT: a complete package for analysing strong and weak hydrogen bonds in macromolecular crystal structures. In Silico Biol 6:651–661. https://content.iospress.com/articles/insilico-biology/isb00337
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Neiderwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652. https://doi.org/10.1056/NEJMoa011573
Kaplan W, Littlejohn TG (2001) Swiss-PDB viewer (deep view). Brief Bioinform 2:195–197. https://doi.org/10.1093/bib/2.2.195
Koebel MR, Schmadeke G, Posner RG, Sirimulla S (2016) AutoDock VinaXB: implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina. J Cheminform. https://doi.org/10.1186/s13321-016-0139-1
Koes, Camacho CJ (2012) ZINCPharmer: pharmacophore search of the ZINC database. Nucl Acid Res 40:W409–W414. https://doi.org/10.1093/nar/gks378
Kortagere S, Ekins S, Welsh WJ (2008) Halogenated ligands and their interactions with amino acids: implications for structure-activity and structure-toxicity relationships. J Mol Graph Model 27:170–177. https://doi.org/10.1016/j.jmgm.2008.04001
Kumar H, Raj U, Gupta S, Tripathi R, Kumar P (2015) Systemic review on chronic myeloid leukemia: therapeutic targets, pathways and inhibitors. J Nucl Med Radiat Ther 6:1–7. https://doi.org/10.4172/2155-9619.1000257
Kurczab R (2017) The evaluation of QM/MM-driven molecular docking combined with MM/GBSA calculations as a halogen-bond scoring strategy. Act Crystallograph B73:188–194. https://doi.org/10.1107/S205252061700138X
Lavecchia A (2014) Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today 20:318–331. https://doi.org/10.1016/j.drudis.2014.10.012
Lu X, Wang Y, Zhu W (2010) Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design. Phys Chem Chem Phys 12:4543–04551. https://doi.org/10.1039/B926326H
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639–1662. https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14%3c1639:AID-JCC10%3e3.0.CO;2-B
Neochoritis CG, Zhao T, Dömling A (2019) Tetrazoles via multicomponent reactions. Chem Rev 119:1970–2024. https://doi.org/10.1021/acs.chemrev.8b00564
O’Hare T, Shakespeare WC et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412. https://doi.org/10.1016/j.ccr.2009.09.028
Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K (2015) Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation. Nature 5:102–105. https://doi.org/10.1038/NATURE14119
Pires DEV, Blundell TL, Ascher DB (2015) pKCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures. J Med Chem 58:4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
Regier A, Khuu P, Oishi K, Shing Ho P (2009) Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 1:74–79. https://doi.org/10.1038/nchem.112
Rose PW, Prlic A, Bi C, Bluhm WF et al (2015) The RCSB protein Data Bank: views of structural biology for basic and applied research and education. Nucl Acids Res 43:345–356. https://doi.org/10.1093/nar/gku1214
Sanner MF (1999) Python: a programming language for software integration and development. J Mol Graph Model 17:57–61. https://doi.org/10.1016/S1093-3263(99)99999-0
Sirimulla S, Bailey JB, Vegesna R, Narayan M (2013) Halogen interactions in protein-ligand complexes: implications of halogen bonding for rational drug design. J Chem Inf Model 53:2781–2791. https://doi.org/10.1021/ci400257k
Swain M (2012) Chemicalize.org. J Chem Inf Model 52:613–615. https://doi.org/10.1021/ci300046g
Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO (2005) Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 48:2534–2547. https://doi.org/10.1021/jm049092j
Vardhan S, Sahoo SK (2020) In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput Biol Med 124:103936. https://doi.org/10.1016/j.compbiomed.2020.103936
Von Bubnoff N, Duyster J (2010) Chronic myelogenous leukemia: treatment and monitoring. Dtsch Arztebl Int 107:114–121. https://doi.org/10.3238/arztebl.2010.0114
Wu P, Nielsen TE, Clausen M (2016) Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 21:5–10. https://doi.org/10.1016/j.drudis.2015.07.008
Yang JM, Chen CCJ (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins 55:288–304. https://doi.org/10.1002/prot.20035
Zhang J, Wang S, Ba Y, Xu Z (2019) Tetrazole hybrids with potential anticancer activity. Eur J Med Chem 178:341–351. https://doi.org/10.1016/j.ejmech.2019.05.071
Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X (2007) Crystal structure of the T315I mutant of Abl kinase. Chem Biol Drug Des 70:171–181. https://doi.org/10.1111/j.1747-0285.2007.00556.x
We thank to CONACyT for the fellowship 305150.
Carlos, C.-G. is grateful for financial support from CIC-UMSNH (14646).
Conflict of interest
The authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Díaz-Cervantes, E., Cortés-García, C.J., Chacón-García, L. et al. Molecular docking and pharmacophoric modelling of 1,5-disubstituted tetrazoles as inhibitors of two proteins present in cancer, the ABL and the mutated T315I kinase. In Silico Pharmacol. 8, 6 (2020). https://doi.org/10.1007/s40203-020-00059-6
- ABL kinase
- Mutant T315I